Regulus Therapeutics Inc ( (RGLS) ) has released its Q4 earnings. Here is a breakdown of the information Regulus Therapeutics Inc presented to its investors.
Regulus Therapeutics Inc., a biopharmaceutical company based in San Diego, focuses on developing innovative medicines targeting microRNAs, primarily for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
In its latest earnings report, Regulus Therapeutics highlighted positive interim results from its Phase 1b clinical trial of farabursen for ADPKD, along with reaching an agreement with the FDA on the design of a Phase 3 trial for potential Accelerated Approval.
The company reported that the interim analysis of the fourth cohort in the Phase 1b trial showed encouraging safety and tolerability, as well as evidence of a mechanistic dose response. Financially, Regulus ended 2024 with $75.8 million in cash, with increased R&D and G&A expenses compared to the previous year, resulting in a net loss of $46.4 million for the year.
Looking forward, Regulus plans to continue advancing farabursen through clinical trials, with the potential for Accelerated Approval by the FDA. The company remains focused on addressing the unmet needs of patients with ADPKD, leveraging its expertise in microRNA-targeting therapies.